| 摘要: |
| 目的探讨非布司他联合秋水仙碱对高尿酸血症患者核苷酸结合寡聚化结构域样受体3（NALP3）、IL-1β的影响。方法将86例高尿酸血症患者按照随机数字表法分为两组，每组43例。观察组采用非布司他联合秋水仙碱治疗，对照组采用别嘌醇联合秋水仙碱治疗。比较两组患者治疗前后血尿酸（BUA）、血肌酐（Scr）、血尿素氮（BUN）、NALP3、IL-1β水平。记录治疗过程中两组不良反应发生情况。结果观察组的疗效显著优于对照组，差异有统计学意义（P＜0.05）；两组治疗后BUA、NALP3、IL-1β水平较治疗前均明显降低（均P＜0.05）；治疗后，观察组BUA、NALP3、IL-1β水平显著低于对照组，差异均有统计学意义（均P＜0.05）；两组患者治疗前后Scr、BUN水平未发生明显改变，差异无统计学意义（P＞0.05）；观察组不良反应的发生率（16.28%）显著低于对照组（25.58%），差异有统计学意义（P＜0.05）。结论非布司他联合秋水仙碱能显著降低高尿酸血症患者血清NALP3、IL-1β的水平，疗效较别嘌醇更好。 |
| 关键词: 非布司他片 秋水仙碱 高尿酸血症 核苷酸结合寡聚化结构域样受体 3 IL-1β |
| DOI：10.12056/j.issn.1006-2785.2017.40.1.2017-584 |
| 分类号: |
| 基金项目:杭州市社会和农业发展入库项目（20163501Y84），萧山科技局引导项目（2016303） |
|
| Efficacy of colchicine combined with febuxostat versus colchicines with allopurinol in treatment of patients with hyperuricemia |
|
|
|
Jinhua People's Hospital
|
| Abstract: |
| Objective To evaluate the efficacy of colchicine combined with febuxostat in treatment of patients with hyperuricemia. Methods Eighty six patients with hyperuricemia were randomly assigned to two groups with 43 cases in each group. Patients in control group were treated by colchicine combined with allopurinol and those in study group were treated by colchicine combined with febuxostat. The serum levels of BUA, Scr, BUN, NALP3 and IL-1β were compared between the two
groups before and after treatment. The adverse reactions of two groups were recorded during the treatment. Results The curative effect of study group was significantly better than that of control group (P＜0.05). After treatment, the BUA, NALP3 and IL-1β levels in both groups were significantly lower than those before treatment (P＜0.05), while Scr and BUN levels did not change significantly before and after treatment(P ＞0.05). After treatment, the BUA, NALP3 and IL-1β levels in study group were significantly lower than those in control group (P ＜0.05). The incidence of adverse reactions in study group (16.28% ) was significantly lower than that in control group (25.58%, P ＜0.05). Conclusion Febuxostat combined with colchicine is more
effective than allopurinol in treatment of patients with hyperuricemia, which is associated with reduced serum IL-1 and NALP3 levels. |
| Key words: Febuxostat tablets Colchicines Hyperuricemia NALP3 IL-1β |
